Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas
Status:
Completed
Trial end date:
2000-04-01
Target enrollment:
Participant gender:
Summary
Major improvements in the treatment of childhood non-lymphoblastic lymphomas have taken place
in the last ten years. Though the survival rate in low risk patients (i.e., those with stage
I & II disease and serum LDH of less than 350 IU/dL) was as high as 90% with the previous
Pediatric Branch protocol, only 32% of patients in the high risk group achieved long term
remission. The present protocol is designed to improve survival in the high risk group by
using alternating non-cross resistant drug regimens. We plan to determine whether using
granulocyte-macrophage colony stimulating factor (GM-CSF) in this group would increase
dose-intensity and ameliorate myelotoxicity. We also plan to study the effect on survival of
decreasing the duration of treatment to three months from the present year-long therapy in
low-risk patients.